Tandem Investment Partners LLC Acquires 273 Shares of Thermo Fisher Scientific Inc. $TMO

Tandem Investment Partners LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.6% in the second quarter, Holdings Channel.com reports. The firm owned 1,821 shares of the medical research company’s stock after purchasing an additional 273 shares during the quarter. Tandem Investment Partners LLC’s holdings in Thermo Fisher Scientific were worth $738,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. CBIZ Investment Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $31,000. DiNuzzo Private Wealth Inc. lifted its holdings in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 3.6%

TMO opened at $543.88 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a market capitalization of $205.37 billion, a P/E ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77. The stock has a fifty day moving average of $482.58 and a 200-day moving average of $447.27.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research reports. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a report on Friday, July 11th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.